PHARMACOKINETICS OF CEFDINIR AND ITS TRANSFER TO DIALYSATE IN PATIENTS WITH CHRONIC-RENAL-FAILURE UNDERGOING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS

Cefdinir (CAS 91832-40-5) was administered orally as a 100-mg capsule (Cefzon(R)) to a total of 12 patients with chronic renal failure under going continuous ambulatory peritoneal dialysis (CAPD) to investigate changes in the serum concentrations, excretion rate Into the dialysate and serum-protein binding of cefdinir. C-max values were 1.63-4.34 mu g/ml, t(1/2) values were 10.8-21.9 h., and AUC values were 31.1-73.1 mu g . h/ml (0-30 h) in four patients given a single oral dose of 100 mg of cefdinir as a capsule. About 1 mu g/ml of cefdinir had still rem ained in the blood of all the patients 24 h after administration. The serum concentrations of cefdinir were dose-dependent in four patients of each group who were given an oral daily dose of 100 mg for 3 to 8 d ays and 200 mg (2 capsules) for 4 to 14 consecutive days. No marked ch ange in laboratory test values or clinical symptoms before and after a dministration were observed in these dose regimes. Protein levels of 5 .17-5.71 g/day were eliminated from the peritoneal dialysate and urine . Cefdinir inhibited 90 to 100% of the clinical isolates such as Staph ylococcus aureus, Staphylococcus epidermidis, Escherichia coli and oth er enteric bacteria causing catheter infection and peritonitis, and it s antibacterial activity was stronger than that of amoxicillin (CAS 26 787-78-0) or cefaclor (CAS 53994-73-3) against these clinical isolates .